We are live on
!
Find out more
ANI Pharmaceuticals
ANIP
ANIP
170 hedge funds and large institutions have $399M invested in ANI Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 68 increasing their positions, 33 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
229% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 14
106% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 33
27% more capital invested
Capital invested by funds: $313M → $399M (+$85.3M)
23% more funds holding
Funds holding: 138 → 170 (+32)
2% more call options, than puts
Call options by funds: $11.9M | Put options by funds: $11.7M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
170
Holders Change
+32
Holders Change %
+23.19%
% of All Funds
4.54%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
46
Increased
68
Reduced
33
Closed
14
Calls
$11.9M
Puts
$11.7M
Net Calls
+$211K
Net Calls Change
-$308K
Top Buyers
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$8.35M |
| 2 |
Renaissance Technologies
New York
|
+$7.32M |
| 3 |
CM
Castleark Management
Chicago,
Illinois
|
+$6.29M |
| 4 |
Bank of New York Mellon
New York
|
+$4.61M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.62M |
